

## LITERATURA

1. WHO. Top ten threats to global health in 2019. [cit. 2024–06–30]. Available from: <https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019>.
2. Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*. 2022;399(10325):629–55.
3. Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. *Lancet*. 2007;369(9560):482–90.
4. Donnan PT, Wei L, Steinke DT, et al. Presence of bacteriuria caused by trimethoprim resistant bacteria in patients prescribed antibiotics: multilevel model with practice and individual patient data. *BMJ*. 2004;328(7451):1297. doi: 10.1136/bmj.328.7451.1297.
5. ECDC. Key message for primary care prescribers. [cit. 2024–06–29]. <https://antibiotic.ecdc.europa.eu/en/get-informed/key-messages/primary-care-prescribers>.
6. Guillemot D, Carbon C, Balkau B, et al. Low Dosage and Long Treatment Duration of Beta-Lactam: risk factors for carriage of penicillin-resistant *Streptococcus pneumoniae*. *JAMA*. 1998;279(5):365–70.
7. Goossens H, Coenen S, Costers M, et al. Achievements of the Belgian Antibiotic Policy Coordination Committee (BAPCOC). *Euro Surveill*. 2008;13(46):19036.
8. Dolk FCK, Pouwels KB, Smith DRM, et al. Antibiotics in primary care in England: which antibiotics are prescribed and for which conditions? *J Antimicrob Chemother*. 2018;73(suppl\_2):ii2–ii1. doi: 10.1093/jac/dkx504.
9. WHO. AWaRe classification of antibiotics for evaluation and monitoring of use, 2023. [cit. 2024–06–29]. Available from: <https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.04>.
10. ECDC. Antimicrobial consumption in EU/EEA (ESAC-Net). Annual Epidemiological Report for 2022. [cit. 2024–06–29]. Available from: <https://www.ecdc.europa.eu/sites/default/files/documents/AER-antimicrobial-consumption.pdf>.
11. HSE. Antibiotic prescribing. [cit. 2024–06–29]. Available from: <https://www.hse.ie/eng/services/list/2/gp/antibiotic-prescribing/background/principles-of-antimicrobial-treatment.html>.
12. Offit PA. Overkill. When modern medicine goes too far. 1<sup>st</sup> ed. Harper 2020. ISBN 978-0062947499.
13. Spellberg B. The New Antibiotic Mantra—„Shorter Is Better“. *JAMA Intern Med*. 2016; 176(9):1254.
14. Gilbert DN, Chambers HF, Saag MS, et al. The Sanford Guide to Antimicrobial Therapy 2024. ISBN 978-1944272272.
15. NICE Guideline NG 138. Pneumonia (community-acquired): antimicrobial prescribing. [cit. 2024–06–29]. Available from: <https://www.nice.org.uk/guidance/ng138/chapter/Recommendations#treatment-for-adults-young-people-and-children>.
16. Společnost všeobecného lékařství ČLS JEP. Antibiotická terapie respiračních, močových a kožních infekcí v ordinaci všeobecného praktického lékaře. Novelizace 2018. DP SVL. [cit. 2024–06–29]. Available from: <https://www.svl.cz/svl-docs/doporučene-postupy/67/antibioticka-terapie-respiracnich-mocovych-a-koznich-infekci-v-ordinaci-vseobecneho-praktickeho-lekare-2018.pdf>.
17. Micromedex. [cit. 2024–06–29]. Available from: <https://www.micromedexsolutions.com/micromedex2/librarian/deeplinkaccess?institution=31u5n877i33c6a9r5t42a1g1e-6n5a210105%5E1466j%5E0f9h23&source=deeplink>.
18. Medscape. Amoxicillin. [cit. 2024–06–29]. Dostupné z <https://reference.medscape.com/drug/amoxil-amoxicillin-342473>.
19. WHO. The WHO AWaRe antibiotic book. [cit. 2024–06–29]. Available from: <https://www.who.int/publications/i/item/9789240062382>.
20. Bieličká JA, Stöhr W, Barratt S, et al. Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial. *JAMA* 2021;326(17):1713.
21. Suzuki HG, Dewez JE, Nijman RG, et al. Clinical practice guidelines for acute otitis media in children: a systematic review and appraisal of European national guidelines. *BMJ Open* 2020;10(5):e035343.
22. SKAP ČLS JEP. Akutní otitis media. [cit. 2024–06–29]. Available from: <https://www.cls.cz/antibioticka-politika>.
23. SKAP ČLS JEP. Akutní sinusitida. [cit. 2024–06–29]. Available from: <https://www.cls.cz/antibioticka-politika>.
24. SKAP ČLS JEP. Komunitní pneumonie. [cit. 2024–06–29]. Available from: <https://www.cls.cz/antibioticka-politika>.
25. SKAP ČLS JEP. Akutní faryngitida, tonzilitida. [cit. 2024–06–29]. Available from: <https://www.cls.cz/antibioticka-politika>.
26. Evans AT, Husain S, Durairaj L, et al. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. *Lancet*. 2002;359(9318):1648–54.
27. Llor C, Moragas A, Bayona C, et al. Efficacy of anti-inflammatory or antibiotic treatment in patients with non-complicated acute bronchitis and discoloured sputum: randomised placebo controlled trial. *BMJ*. 2013; 347: f5762–f5762.
28. Česká společnost otorinolaryngologie a chirurgie hlavy a krku. Příručka pro praxi: akutní středoušní zánět. [cit. 2024–06–29]. Available from: <https://www.otorinolaryngologie.cz/content/uploads/2020/02/ppp-oma.pdf>.
29. Klein JO. Microbiologic efficacy of antibacterial drugs for acute otitis media. *Pediatr Infect Dis J*. 1993;12(12):973–5.
30. Frost HM, Keith A, Fletcher DR, et al. Clinical Outcomes Associated with Amoxicillin Treatment for Acute Otitis Media in Children. *J Pediatr Infect Dis Soc*. 2024;13(3):203–10.
31. Česká společnost otorinolaryngologie a chirurgie hlavy a krku. Příručka pro praxi: akutní rinosinusitida. [cit. 2024–06–29]. Available from: <https://www.otorinolaryngologie.cz/content/uploads/2020/02/ppp-ars.pdf>.
32. NICE Guideline NG 79. Sinusitis (acute): antimicrobial prescribing. [cit. 2024–06–29]. Available from: <https://www.nice.org.uk/guidance/ng79>.
33. Sundhed. Bihulebeandelse, akut. [cit. 2024–06–29]. Available from: <https://www.sundhed.dk/sundhedsfaglig/laegehaandbogen/oere-naese-hals/tilstande-og-sygdomme/naese-og-bihuler/bihulebetaendelse-akut/>.
34. Helsedirektoratet. Antibiotika. [cit. 2024–06–29]. Available from: <https://www.helse-direktoratet.no/tema/antibiotika>.
35. Folkhälsomyndigheten. Behandlingsrekommendationer för vanliga infektioner i öppenvård. [cit. 2024–06–29]. Available from: <https://www.folkhalsomyndigheten.se/contentassets/246aa17721b44c5380a0117f6d0aba40/behandlingsrekommendationer-oppenvard.pdf>.
36. Lindbaek M, Hjortdahl P, Johnsen ULH. Randomised, double blind, placebo controlled trial of penicillin V and amoxicillin in treatment of acute sinus infections in adults. *BMJ* 1996;313(7053):325–9.
37. Skoog Ståhlgren G, Tyrstrup M, Edlund C, et al. Penicillin V four times daily for five days versus three times daily for 10 days in patients with pharyngotonsillitis caused by group A streptococci: randomised controlled, open label, non-inferiority study. *BMJ* 2019; I5337. Available from: DOI: doi: 10.1136/bmj.I5337.
38. Watkins DA, Johnson CO, Colquhoun SM, et al. Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015. *N Engl J Med*. 2017;377(8):713–22.
39. Shulman ST, Stollerman G, Beall B, et al. Temporal Changes in Streptococcal M Protein Types and the Near-Disappearance of Acute Rheumatic Fever in the United States. *Clin Infect Dis*. 2006; 42(4):441–7.
40. Edouard S, Michel-Lepage A, Raoult D. Does it make sense to detect *Streptococcus pyogenes* during tonsillitis in Europe to prevent acute rheumatic fever? *Clin Microbiol Infect*. 2014;20(12):O981–2.
41. NHS England. Group A *Streptococcus*: reinstatement of NICE sore throat guidance for children and young people and withdrawal of NHS England interim guidance. [cit. 2024–06–29]. Available from: <https://www.england.nhs.uk/publication/group-a-streptococcus-communications-to-clinicians/>.
42. Burk M, El-Kersh K, Saad M, et al. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. *Eur Respir Rev*. 2016;25(140):178–88.
43. Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. *Clin Infect Dis*. 2016;62(7):817–23.
44. NICE Guideline CG191. Pneumonia in adults: diagnosis and management. [cit. 2024–06–29]. Available from: <https://www.nice.org.uk/guidance/cg191>.
45. SKAP ČLS JEP. Asymptomatická bakterieurie. [cit. 2024–06–29]. Available from: <https://www.cls.cz/antibioticka-politika>.
46. SKAP ČLS JEP. Akutní sporadická a recidivující nekomplikovaná cystitida u žen. [cit. 2024–06–29]. Available from: <https://www.cls.cz/antibioticka-politika>.
47. SKAP ČLS JEP. Akutní nekomplikovaná pyelonefritida. [cit. 2024–06–29]. Dostupné z <https://www.cls.cz/antibioticka-politika>.
48. Kayalp D, Dogan K, Ceylan G, et al. Can routine automated urinalysis reduce culture requests? *Clin Biochem*. 2013;46(13–14):1285–9.
49. EAU Guidelines. Urological Infections. [cit. 2024–06–29]. Available from: <https://uroweb.org/guidelines/urological-infections>.
50. NICE Guideline NG109. Urinary tract infection (lower): antimicrobial prescribing. [cit. 2024–06–29]. Dostupné z <https://www.nice.org.uk/guidance/ng109>.
51. Huttner A, Kowalczyk A, Turjeman A, et al. Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. *JAMA* 2018;319(17):1781–1789.
52. NICE Guideline NG111. Pyelonephritis (acute): antimicrobial prescribing. [cit. 2024–06–29]. Available from: <https://www.nice.org.uk/guidance/ng111>.
53. SKAP ČLS JEP. Impetigo. [cit. 2024–06–29]. Available from: <https://www.cls.cz/antibioticka-politika>.
54. NICE Guideline NG153. Impetigo: antimicrobial prescribing. [cit. 2024–06–29]. Available from: <https://www.nice.org.uk/guidance/ng153>.
55. SKAP ČLS JEP. Erysipel a flegmóna. [cit. 2024–06–29]. Dostupné z <https://www.cls.cz/antibioticka-politika>.
56. NICE Guideline NG141. Cellulitis and erysipelas: antimicrobial prescribing. [cit. 2024–06–29]. Available from: <https://www.nice.org.uk/guidance/ng141>.